Hoth Therapeutics Licenses Lupus Therapeutic Back to Zylö Therapeutics
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs, is pleased to announce that it has entered into an agreement with Zylö Therapeutics to license its novel cannabinoid therapeutic, HT-005 for lupus patients, back to Zylö. Read more >>